Nektar Therapeutics (NKTR)
1.27
+0.01
(+0.79%)
USD |
NASDAQ |
May 31, 16:00
1.34
+0.07
(+5.51%)
After-Hours: 20:00
Nektar Therapeutics Enterprise Value: -56.03M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | -56.03M |
| May 30, 2024 | -57.87M |
| May 29, 2024 | -35.84M |
| May 28, 2024 | -13.80M |
| May 24, 2024 | 11.91M |
| May 23, 2024 | 15.58M |
| May 22, 2024 | 32.11M |
| May 21, 2024 | 22.92M |
| May 20, 2024 | 32.11M |
| May 17, 2024 | 33.02M |
| May 16, 2024 | 41.29M |
| May 15, 2024 | 46.80M |
| May 14, 2024 | 35.78M |
| May 13, 2024 | 32.11M |
| May 10, 2024 | 33.94M |
| May 09, 2024 | 4.561M |
| May 08, 2024 | 11.91M |
| May 07, 2024 | -13.80M |
| May 06, 2024 | 13.74M |
| May 03, 2024 | -0.9474M |
| May 02, 2024 | 17.42M |
| May 01, 2024 | 13.74M |
| April 30, 2024 | -21.15M |
| April 29, 2024 | -21.15M |
| April 26, 2024 | -46.85M |
| Date | Value |
|---|---|
| April 25, 2024 | -46.85M |
| April 24, 2024 | -35.84M |
| April 23, 2024 | -28.49M |
| April 22, 2024 | -39.51M |
| April 19, 2024 | -61.54M |
| April 18, 2024 | -46.85M |
| April 17, 2024 | -41.35M |
| April 16, 2024 | -15.64M |
| April 15, 2024 | -0.948M |
| April 12, 2024 | 17.41M |
| April 11, 2024 | 0.8882M |
| April 10, 2024 | -52.36M |
| April 09, 2024 | -59.71M |
| April 08, 2024 | -48.69M |
| April 05, 2024 | -46.85M |
| April 04, 2024 | -46.85M |
| April 03, 2024 | -98.27M |
| April 02, 2024 | -114.80M |
| April 01, 2024 | -123.22M |
| March 31, 2024 | -117.70M |
| March 28, 2024 | -132.08M |
| March 27, 2024 | -141.10M |
| March 26, 2024 | -138.36M |
| March 25, 2024 | -140.54M |
| March 22, 2024 | -135.88M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-384.62M
Minimum
Mar 30 2023
5.078B
Maximum
Jul 03 2019
1.287B
Average
1.543B
Median
Enterprise Value Benchmarks
| Cara Therapeutics Inc | -34.50M |
| Stereotaxis Inc | 147.33M |
| Vanda Pharmaceuticals Inc | -95.58M |
| Avid Bioservices Inc | 623.63M |
| Rigel Pharmaceuticals Inc | 181.65M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -36.80M |
| Revenue (Quarterly) | 21.64M |
| Total Expenses (Quarterly) | 56.09M |
| EPS Diluted (Quarterly) | -0.19 |
| Gross Profit Margin (Quarterly) | 60.56% |
| Profit Margin (Quarterly) | -170.1% |
| Earnings Yield | -72.44% |
| Normalized Earnings Yield | -59.31 |